![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » SYNTONIX, BOEHRINGER DEAL COULD BE WORTH $63 MILLION
SYNTONIX, BOEHRINGER DEAL COULD BE WORTH $63 MILLION
October 24, 2005
Syntonix Pharmaceuticals Inc., based in Waltham, and German company Boehringer Ingelheim have entered into a collaboration to optimize certain Boehringer Ingelheim therapeutic peptides for inhalation, using Syntonix's SynFusion and Transceptor technologies. Syntonix will receive an upfront fee and research support of up to $63 million.
Mass High Tech (http://www.masshightech.com/displayarticledetail.asp?Art_ID=70044)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct